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Please note: 
Within this document you find general information about the drug of interest and the indication it is 
intended to be used for. Further we have included full text publications of phase III trials, assessing 
the safety and efficacy of the drugs of interest. 
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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), nine information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every three months, these anticancer therapies are filtered (i.e. in most cases defined as 
availability of phase III results; for orphan drugs also phase II) to identify drugs at/around the same 
time as the accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies five prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 39th prioritisation (April 2019), 10 drugs were filtered out of 507 identified and were sent to 
prioritisation. Of these, three drugs were ranked as ‘highly relevant’ by the expert panel, seven as 
‘relevant’ and none as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for 
example, abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
 
No Filtered Drugs – 39
th
 prioritisation 2
nd
 quarter 2019 Overall category 
1. Avelumab (Bavencio®) plus axitinib versus sunitinib for advanced 
renal-cell carcinoma (RCC)  
Relevant 
2. Pembrolizumab (Keytruda®) plus axitinib versus sunitinib for 
advanced RCC 
Relevant 
3. Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-
positive, peripheral T-cell lymphoma 
Highly relevant 
4. Darolutamide (ODM-201) in nonmetastatic, castration-resistant 
prostate cancer (CRPC)  
Highly relevant 
5. Adjuvant denosumab (Xgeva®, Prolia®) in postmenopausal 
patients with hormone receptor-positive breast cancer 
Relevant 
6. Ibrutinib (Imbruvica®) plus obinutuzumab versus chlorambucil plus 
obinutuzumab in first-line treatment of chronic lymphocytic 
leukaemia (CLL) 
Highly relevant 
7. Oral ixazomib (Ninlaro®) maintenance following ASCT 
(TOURMALINE-MM3) 
Relevant 
8. PD-1 blockade with pembrolizumab (Keytruda®) in advanced 
Merkel-cell carcinoma (MCC)  
Relevant 
9. Ramucirumab (Cyramza®) after sorafenib in patients with 
advanced hepatocellular carcinoma (HCC) and increased α-
fetoprotein concentrations 
Relevant 
10. Sorafenib (Nexavar®) for advanced and refractory desmoid 
tumours 
Relevant 
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Lymphoma 
Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-
positive, peripheral T-cell lymphoma 
Overview 
Drug Description 
brentuximab vedotin is an antibody-drug conjugate composed of a CD30-
directed monoclonal antibody that is covalently linked to the 
antimicrotubule agent monomethyl auristatin E (MMAE) 
Patient Indication patients with previously untreated, CD30-positive peripheral T-cell lymphoma  
Incidence in 
Austria 
approx. 10% of newly diagnosed non-Hodgkin-lymphomas (NHLs) are T-
cell lymphomas. NHL: 1,333 newly diagnosed per year (2016), 
15.5/100,000 persons/year (2016) (European Standard Population 2013) 
[1] 
Current standard 
treatment 
a the most common peripheral T-cell lymphomas are nodal 
peripheral T-cell lymphomas, including peripheral T-cell lymphoma 
not otherwise specified, angioimmunoblastic T-cell lymphoma, and 
ALK-positive or ALK-negative systemic anaplastic large cell 
lymphoma.  
a for the first-line treatment, strategies should be adapted according 
to factors such as age, international prognostic index (IPI), and co-
morbidity that define a patient’s eligibility for dose-intensified 
approaches 
a whenever possible, inclusion in a clinical trial is recommended 
a cyclophosphamide, hydroxydaunorubicin, vincristine and 
prednisone (CHOP), or variants of it, has been the most 
commonly used regimen in nodal peripheral T-cell lymphomas [2, 
3] 
Ongoing Phase III  NCT01777152 (ECHELON-2) until 12/2019 [4] 
Approval 
status for 
this 
indication 
[5, 6] 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
[5, 6] 
EMA 
according to product information (03/2019), brentuximab vedotin is 
indicated:  
a for adult patients with previously untreated CD30+ Stage IV 
Hodgkin lymphoma (HL) in combination with doxorubicin, 
vinblastine and dacarbazine (AVD) 
a for the treatment of adult patients with CD30+ HL at increased risk 
of relapse or progression following ASCT  
a for the treatment of adult patients with relapsed or refractory 
CD30+ HL 
- following ASCT, or  
- following at least two prior therapies when ASCT or multi -
agent chemotherapy is not a treatment option. Brentuximab 
vedotin is indicated for the treatment of adult patients with 
relapsed or refractory systemic anaplastic large cell 
lymphoma (sALCL) 
a for the treatment of adult patients with CD30+ cutaneous T-cell 
lymphoma (CTCL) after at least 1 prior systemic therapy  
FDA 
according to label information (11/2018), brentuximab vedotin is indicated 
for the treatment of adult patients with: 
a previously untreated Stage III or IV cHL, in combination with 
doxorubicin, vinblastine, and dacarbazine  
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a cHL at high risk of relapse or progression as post-autologous 
hematopoietic stem cell transplantation (auto-HSCT) consolidation  
a cHL after failure of auto-HSCT or after failure of at least two prior 
multi-agent chemotherapy regimens in patients who are not auto- 
HSCT candidates  
a previously untreated sALCL or other CD30-expressing peripheral 
T-cell lymphomas (PTCL), including angioimmunoblastic T-cell 
lymphoma and PTCL not otherwise specified, in combination with 
cyclophosphamide, doxorubicin, and prednisone  
a sALCL after failure of at least one prior multi-agent chemotherapy 
regimen  
a primary cutaneous anaplastic large cell lymphoma (pcALCL) or 
CD30-expressing mycosis fungoides (MF) who have received 
prior systemic therapy. 
Costs  
Adcetris ® 50 mg powder for concentrate for solution for infusion = € 
3,333.00 (ex-factory price) [7]. 
 
ECHELON-2 patients received cyclophosphamide 750 mg/m² and 
doxorubicin 50 mg/m² on day 1 of each cycle intravenously and 
prednisone 100 mg once daily on days 1 to 5 of each cycle orally, followed 
by either brentuximab vedotin 1.8 mg/kg and a placebo form of vincristine 
intravenously (A+CHP group) or vincristine 1.4 mg/m² and a placebo form 
of brentuximab vedotin intravenously (CHOP group) on day 1 of each 
cycle. The number of the 21-day cycles (six or eight) was decided 
at the investigator’s discretion at registration. 
 
Based on study treatment and assuming an average body weight of 70 kg, 
one dose of brentuximab vedotin would cost approx. € 9,999.00 (6 cycles 
= approx. € 59,994.00) . 
1.1.1 Published articles (PubMed): 
The Lancet; available online December 4, 2018 (Horwitz et al.): “Brentuximab vedotin with 
chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, 
randomised, phase 3 trial” [2] 
Background  
Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the 
ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, 
cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, 
vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell 
lymphomas. 
 
Methods  
ECHELON-2 is a double-blind, double-dummy, randomised, placebo-controlled, active-comparator 
phase 3 study. Eligible adults from 132 sites in 17 countries with previously untreated CD30-
positive peripheral T-cell lymphomas (targeting 75% with systemic anaplastic large cell lymphoma) 
were randomly assigned 1:1 to receive either A+CHP or CHOP for six or eight 21-day cycles. 
Randomisation was stratified by histological subtype according to local pathology assessment and 
by international prognostic index score. All patients received cyclophosphamide 750 mg/m² and 
doxorubicin 50 mg/m² on day 1 of each cycle intravenously and prednisone 100 mg once daily on 
days 1 to 5 of each cycle orally, followed by either brentuximab vedotin 1.8 mg/kg and a placebo 
form of vincristine intravenously (A+CHP group) or vincristine 1.4 mg/m² and a placebo form of 
brentuximab vedotin intravenously (CHOP group) on day 1 of each cycle. The primary endpoint, 
progression-free survival according to blinded independent central review, was analysed by intent-
to-treat. This trial is registered with ClinicalTrials.gov, number NCT01777152. 
 
Findings  
Between Jan 24, 2013, and Nov 7, 2016, 601 patients assessed for eligibility, of whom 452 patients 
were enrolled and 226 were randomly assigned to both the A+CHP group and the CHOP group. 
Median progression-free survival was 48.2 months (95% CI 35.2–not evaluable) in the A+CHP 
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group and 20.8 months (12.7–47.6) in the CHOP group (hazard ratio 0.71 [95% CI 0.54–0.93], 
p=0.0110). Adverse events, including incidence and severity of febrile neutropenia (41 [18%] 
patients in the A+CHP group and 33 [15%] in the CHOP group) and peripheral neuropathy (117 
[52%] in the A+CHP group and 124 [55%] in the CHOP group), were similar between groups. Fatal 
adverse events occurred in seven (3%) patients in the A+CHP group and nine (4%) in the CHOP 
group. 
 
Interpretation  
Front-line treatment with A+CHP is superior to CHOP for patients with CD30-positive peripheral T-
cell lymphomas as shown by a significant improvement in progression-free survival and overall 
survival with a manageable safety profile. 
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Prostate Cancer 
Darolutamide (ODM-201) in nonmetastatic, castration-resistant 
prostate cancer (CRPC) 
Overview 
Drug Description darolutamide is an androgen-receptor antagonist 
Patient Indication men with nonmetastatic CRPC 
Incidence in 
Austria 
5,245 newly diagnosed per year (2016), 138.3/100,000 men/year (2016) 
(European Standard Population, 2013) [8] 
Current standard 
treatment 
a there are several treatment options available to patients with 
non‐metastatic CRPC 
a many men with localised prostate cancer will not benefit from 
definitive treatment, and 45% of men with prostate-specific antigen 
(PSA)‐detected prostate cancer are candidates for deferred 
management (watchful waiting) 
a in men with comorbidity and limited life expectancy, treatment of 
localized prostate cancer may be deferred to avoid loss of quality  
a European Association of Urology (EAU) - European Society for 
Radiotherapy & Oncology (ESTRO) - International Society of 
Geriatric Oncology (SIOG) - guidelines recommend the use of: 
- watchful waiting or observation 
- radical prostatectomy (surgical removal of the entire 
prostate gland between the urethra and bladder) 
- external beam radiotherapy 
- brachytherapy (trans‐perineal implantation of radioactive 
seeds into the prostate) 
- cryotherapy (local or general use of low temperatures in 
medical therapy) 
- hormone therapy (androgen deprivation or 
anti‐androgens) 
a treatment recommendations are dependent on the disease and 
patient characteristics, currently there is no standard treatment for 
castrated patients with rising PSA and no evidence of metastases 
[9]. 
Ongoing Phase III 
[4] NCT02200614 (ARAMIS) until 06/2020 
Approval 
status for 
this 
indication 
[5, 6] 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
[5, 6] 
EMA - 
FDA - 
Costs  -  
1.1.2 Published articles (PubMed): 
NEJM; available online February 14, 2019 (Fizazi et al.): “Darolutamide in Nonmetastatic, 
Castration-Resistant Prostate Cancer” [10] 
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Background  
Darolutamide is a structurally unique androgen-receptor antagonist that is under development for 
the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis 
and death in men with nonmetastatic, castration-resistant prostate cancer. 
 
Methods  
We conducted a randomized, double-blind, placebo-controlled, phase 3 trial involving men with 
nonmetastatic, castration-resistant prostate cancer and a prostate-specific antigen doubling time of 
10 months or less. Patients were randomly assigned in a 2:1 ratio to receive darolutamide (600 mg 
[two 300-mg tablets] twice daily) or placebo while continuing androgen-deprivation therapy. The 
primary end point was metastasis- free survival, with the presence of metastasis determined by 
independent central review of radiographic imaging every 16 weeks. 
 
Findings  
In total, 1509 patients underwent randomization (955 to the darolutamide group and 554 to the 
placebo group). In the planned primary analysis, which was performed after 437 primary end-point 
events had occurred, the median metastasis-free survival was 40.4 months with darolutamide, as 
compared with 18.4 months with placebo (hazard ratio for metastasis or death in the darolutamide 
group, 0.41; 95% confidence interval, 0.34 to 0.50; P<0.001). Darolutamide was also associated 
with benefits with regard to all secondary end points, including overall survival, time to pain 
progression, time to cytotoxic chemotherapy, and time to a symptomatic skeletal event. The 
incidence of adverse events that occurred or worsened during the treatment period and had a 
frequency of 5% or more or were of grade 3 or higher was similar in the two groups; all such events 
except fatigue occurred in less than 10% of patients in either group. The percentage of patients 
who discontinued the assigned regimen because of adverse events was 8.9% in the darolutamide 
group and 8.7% in the placebo group. Darolutamide was not associated with a higher incidence of 
seizures, falls, fractures, cognitive disorder, or hypertension than placebo. 
 
Interpretation  
Among men with nonmetastatic, castration-resistant prostate cancer, metastasis-free survival was 
significantly longer with darolutamide than with placebo. The incidence of adverse events was 
similar for darolutamide and placebo. (Funded by Bayer HealthCare and Orion Pharma; ARAMIS 
ClinicalTrials.gov number, NCT02200614.) 
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Leukaemia 
Ibrutinib (Imbruvica®) plus obinutuzumab versus chlorambucil 
plus obinutuzumab in first-line treatment of chronic lymphocytic 
leukaemia (CLL) 
Overview 
Drug Description ibrutinib is an oral inhibitor of tyrosine-protein kinase (BTK) 
Patient Indication patients with untreated, active CLL or small lymphocytic lymphoma (SLL) 
Incidence in 
Austria 
leukaemia: 1,007 newly diagnosed per year (2016), 11.8/100,000 
persons/year (2016) (European Standard Population, 2013) [11] 
Current standard 
treatment 
a the choice of first-line therapy of patients with CLL depends on the 
presence of any comorbidities, genetic status, renal function and 
to a lesser extent patient age 
a wherever possible, the therapy should take place within the 
framework of a clinical trial 
a patients without del(17p13) or TP53 mutation: 
- physically fit patients: combination therapy with 
fludarabine, cyclophosphamide and rituximab (FCR); 
alternatively: combination of bendamustine with rituximab 
- unfit patients: chlorambucil or bendamustine 
- frail patients: supportive therapy is paramount (this may 
also include administration of antineoplastic drugs such as 
steroids, chlorambucil, bendamustine or rituximab at 
adapted doses 
a patients with a confirmed del(17p13) or TP53 mutation: 
- in patients without relevant comorbidity but with CLL 
requiring therapy there are alternative approaches 
available for first-line therapy such as ibrutinib, 
idelalisib/rituximab or alemtuzumab  
- the indication for allogeneic blood stem cell 
transplantation should be given critical consideration after 
weighing up of individual risks considering age, 
comorbidities, and the availability of perfectly matched 
donors. 
Ongoing Phase III 
[4] 
NCT02264574 (iLLUMINATE) until 01/2020 
NCT03701282 until10/2025 
NCT02863718 until 04/2022 
NCT02048813 until 03/2020 
NCT01886872 until 02/2019 
NCT03737981 until 06/2027 
NCT02950051 until 01/2024 
Approval 
status for 
this 
indication 
[5, 6] 
EMA - 
FDA 
according to label information (01/2019), ibrutinib is indicated for the 
treatment of adult patients with: 
a CLL/SLL 
a CLL/SLL with 17p deletion 
Approval 
status for 
other 
indications 
[5, 6] 
EMA 
according to product information (08/2018), ibrutinib is indicated: 
a as a single agent for the treatment of adult patients with relapsed 
or refractory mantle cell lymphoma (MCL) 
a as a single agent for the treatment of adult patients with previously 
untreated CLL 
a as a single agent or in combination with bendamustine and 
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rituximab for the treatment of adult patients with CLL who have 
received at least one prior therapy 
a as a single agent for the treatment of adult patients with 
Waldenström’s macroglobulinaemia (WM) who have received at 
least one prior therapy, or in first line treatment for patients 
unsuitable for chemo-immunotherapy. 
FDA 
according to label information (01/2019), ibrutinib is indicated for the 
treatment of adult patients with: 
a MCL who have received at least one prior therapy  
a Waldenström’s macroglobulinaemia (WM)  
a marginal zone lymphoma (MZL) who require systemic therapy and 
have received at least one prior anti-CD20-based therapy   
a chronic graft versus host disease (cGVHD) after failure of one or 
more lines of systemic therapy  
Costs  
  90 Imbruvica® hard capsules 140 mg = € 5474.70 (ex-factory price) [7] 
120 Imbruvica® hard capsules 140 mg = € 7299.60 (ex-factory price) [7] 
 
iLLUMINATE trial patients received oral ibrutinib at a dose of 420 mg once 
daily continuously combined with intravenous obinutuzumab for a total of 6 
(28-day-)cycles. 
Based on study treatment, one month of ibrutinib treatment would cost 
approx. € 5474.70 (6 cycles = € 32,848.20); additionally, costs for 
obinutuzumab treatment would incur. 
1.1.3 Published articles (PubMed): 
Lancet Oncol 2019; 20: 43–56, 3 December 2018 (Moreno et al.): “Ibrutinib plus obinutuzumab 
versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia 
(iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial” [12] 
 
Background  
Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to 
chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia. 
We compared the efficacy of the combination of ibrutinib plus obinutuzumab with chlorambucil plus 
obinutuzumab in first-line chronic lymphocytic leukaemia or small lymphocytic lymphoma. 
 
Methods  
iLLUMINATE is a multicentre, randomised, open-label, phase 3 trial done at 74 academic and 
community hospitals in Australia, Canada, Israel, New Zealand, Russia, Turkey, the EU, and the 
USA in patients with previously untreated chronic lymphocytic leukaemia or small lymphocytic 
lymphoma, either aged 65 years or older or younger than 65 years with coexisting conditions. 
Patients were randomly assigned (1:1) using a blocked randomisation schedule, stratified by 
Eastern Cooperative Oncology Group performance status and cytogenetics, to receive ibrutinib 
plus obinutuzumab (oral ibrutinib [420 mg once daily continuously] combined with intravenous 
obinutuzumab [100 mg on day 1, 900 mg on day 2, 1000 mg on day 8, and 1000 mg on day 15 of 
cycle 1 and on day 1 of subsequent 
28-day cycles, for a total of six cycles]) or chlorambucil plus obinutuzumab (oral chlorambucil [0·5 
mg/kg bodyweight on days 1 and 15 of each 28-day cycle for six cycles] combined with the same 
obinutuzumab regimen). Allocation concealment was achieved using an interactive web response 
system. Patients and investigators were not masked to treatment assignment. The primary 
endpoint was progression-free survival assessed by a masked independent review committee in 
the intention-to-treat population. Safety was assessed in all patients who received at least one 
dose of study treatment. This study is registered with ClinicalTrials.gov (NCT02264574), and 
patient enrolment is complete.  
 
Findings  
Between Oct 6, 2014, and Oct 12, 2015, 229 patients were enrolled and randomly assigned to 
receive ibrutinib plus obinutuzumab (n=113) or chlorambucil plus obinutuzumab (n=116). After a 
median follow-up of 31.3 months (IQR 29.4–33.2), median progression-free survival was 
significantly longer in the ibrutinib plus obinutuzumab group (median not reached [95% CI 33.6–
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non-estimable]) than in the chlorambucil plus obinutuzumab group (19.0 months [15.1–22.1]; 
hazard ratio 0.23; 95% CI 0.15–0.37; p<0.0001). Estimated 30-month progression-free survival 
was 79% (95% CI 70–85) in the ibrutinib plus obinutuzumab group and 31% (23–40) in the 
chlorambucil plus obinutuzumab group. The most common grade 3 or 4 adverse events in both 
groups were neutropenia and thrombocytopenia. Serious adverse events occurred in 65 (58%) of 
113 patients treated with ibrutinib plus obinutuzumab and 40 (35%) of 115 patients treated with 
chlorambucil plus obinutuzumab. Ibrutinib or chlorambucil treatment-related deaths were reported 
in one (1%) of 113 patients in the ibrutinib plus obinutuzumab group (sudden death) and one (1%) 
of 115 patients in the chlorambucil plus obinutuzumab group (neuroendocrine carcinoma of the 
skin). 
 
Interpretation  
Ibrutinib plus obinutuzumab is an efficacious and safe chemotherapy-free combination treatment in 
previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma 
independent of high-risk features and provides an alternative first-line treatment option for these 
patients. 
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